Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery

Clinical trial NCT06678399 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06678399
Sponsor: Kelifarma
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Preemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery

Start date: 2025-04-01
Primary completion: 2026-10-01
Enrollment: 91

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.